Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Solventum Corporation (SOLV) — XLV Health Care · S&P 500 Profile |Solventum公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Solventum Corporation (SOLV) — Business, History & S&P 500 Profile |Solventum公司介紹

Solventum company profile · wound care, dental and health information systems · history · financial snapshot · S&P 500 rank #450 · Solventum公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 4, 2026 (Slickcharts / StockAnalysis benchmark)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$14.43B
Nov 4, 2026 · StockAnalysis
S&P 500 WEIGHT
0.02%
Rank #450 · Nov 4, 2026 (Slickcharts)
FY2025 NET SALES
$8.33B
+0.9% YoY · MedSurg 57.9% of net sales
FY2025 NET INCOME
$1.56B
Diluted EPS $8.88 · Incl. Purification & Filtration sale gain

SNAPSHOT

TickerSOLV (NYSE)
CompanySolventum Corporation
GICS sector / industryHealth Care / Health Care Technology
S&P 500 rank (by weight)#450 · 0.02% (Nov 4, 2026)
Sector rank (by S&P 500 weight)#52 in Health Care (Nov 4, 2026)
HeadquartersMaplewood, Minnesota
Founded2024, spun off from 3M (separation completed April 1, 2024); previously part of 3M’s Health Care business
CEOBryan Hanson (president & CEO)
Employees≈20,000 employees (FY2025 10-K)
Market cap$14.43B (Nov 4, 2026)
SEC filingsEDGAR — CIK 0001964738

WHAT IT DOES

Solventum is a healthcare company separated from 3M on April 1, 2024. It reports three segments: MedSurg (negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, IV site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, electrodes and OEM technologies); Dental Solutions (brackets, aligners, restorative cements and bonding agents spanning prevention, restoration, replacement and malocclusion); and Health Information Systems (computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition and data visualization, designed to eliminate revenue-cycle waste and support value-based care).

FY2025 was the company’s first full calendar year as a standalone company. Net sales were $8.33B, up 0.9%, and net income was $1.56B, or $8.88 per diluted share, against $479M, or $2.76, in 2024. That comparison is not a clean trend measure: 2025 includes the gain on the sale of Purification and Filtration (completed September 1, 2025) inside Corporate and Unallocated, and 2024 comparatives straddle the spin-off. Adjusted diluted EPS (non-GAAP) was $6.11, down 8.8% from $6.70. The 10-K itself warns that historical pre-spin financial information is carve-out information and is not necessarily representative of standalone results — pre-spin standalone figures are therefore not presented as standalone comparables in this profile.

Purification and Filtration, sold on September 1, 2025 under an agreement dated February 25, 2025, contributed $497M of net sales in FY2025, covering only the pre-sale period. The retained Water Business, previously part of Purification and Filtration, is reported in All Other together with sales under 3M supply agreements. In December 2025 Solventum acquired Acera as a wholly owned subsidiary; total assets and net sales of the acquired business were each under 1% of consolidated amounts at December 31, 2025.

SEGMENTS — FY2025 NET SALES

SegmentNet salesShareYoY
MedSurg$4.82B57.9%+3.9%
Dental Solutions$1.35B16.2%+4.2%
Health Information Systems$1.36B16.3%+4.1%
Purification and Filtration$0.50B6.0%−29.9%
All Other$0.30B3.6%−1.3%
Net sales by segment as disclosed in Note 18 of the FY2025 10-K; the five rows sum to $8,325M. FY2024 comparatives: MedSurg $4,637M, Dental Solutions $1,295M, Health Information Systems $1,306M, Purification and Filtration $709M, All Other $306M. Purification and Filtration was sold on September 1, 2025, so FY2025 sales cover only the pre-sale period. From the third quarter of 2025 the company reports three segments (MedSurg, Dental Solutions, Health Information Systems), with the retained Water Business in All Other. Reportable segment net sales were $7,526M (FY2024 $7,238M).

HISTORY

YearMilestone
Before 2024The business operates as 3M’s Health Care business; its historical financial information is carve-out information, not standalone results.
2024The separation from 3M is completed on April 1, 2024; Solventum lists on the NYSE as an independent publicly traded company.
2025Solventum agrees on February 25, 2025 to sell Purification and Filtration and completes the sale on September 1, 2025; in December 2025 it acquires Acera as a wholly owned subsidiary.

COMPETITIVE POSITION

  • MedSurg is the anchor (57.9% of FY2025 net sales, $810M of segment operating income) with wound-care and surgical brands sold into hospitals worldwide.
  • Dental Solutions and Health Information Systems are smaller adjacencies, both growing about 4% in 2025; Health Information Systems produced segment operating income of $496M on $1,360M of net sales.
  • Against diversified medtech peers such as Medtronic and BD, Solventum is a pure play on wound care, dental and health information technology — smaller, and still building its standalone cost base after the spin-off.

FINANCIAL SNAPSHOT — FY2025

Net sales$8.33B
Total operating income$2.18B
Income before income taxes$1.71B
Net income$1.56B
Diluted EPS$8.88
Adjusted diluted EPS (non-GAAP)$6.11
Net interest expense$347M
FY2025 ended Dec 31, 2025; Form 10-K filed Feb 27, 2026. Prior-year figures: net sales $8.25B, net income $479M, diluted EPS $2.76, so net sales grew 0.9% and net income grew 224.8% (computed). The net-income comparison is not a clean trend measure: 2025 includes the gain on the Purification and Filtration sale (completed September 1, 2025) in Corporate and Unallocated, and 2025 is the first full calendar year as a standalone company after the April 1, 2024 spin-off from 3M; pre-spin figures are carve-out figures, not standalone results. Adjusted diluted EPS (non-GAAP) was $6.11, down 8.8% from $6.70. Total operating income of $2,181M is from the Note 18 reconciliation (reportable segments $1,652M, Purification and Filtration $96M, All Other $42M, amortization −$312M, Corporate and Unallocated +$702M).

KEY RISKS

  • Spin-off dependencies: 3M transition and supply agreements and standalone costs remain material; the 10-K risk summary leads with these items.
  • Regulatory and product-liability exposure in MedSurg: wound-care and surgical products face FDA regulation and liability claims.
  • Dental and health-information competition and health-system customer concentration: both smaller segments compete with larger, diversified suppliers.
  • Debt carried from the spin-off (net interest expense $347M in 2025) and reduced scale and diversification after the Purification and Filtration sale.

WHY IT MATTERS FOR THE S&P 500

Solventum is the S&P 500’s newest standalone health-care name: wound-care volumes, dental demand and health-information software adoption read as gauges of hospital spending, dental visits and the shift to value-based care. At rank #450 by weight (0.02%) — Health Care #52 — it is a spin-off still proving its standalone cost structure after its first full year outside 3M.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Nov 4, 2026 crawl) · StockAnalysis (market cap — Nov 4, 2026 crawl, single source)
FinancialsForm 10-K for FY2025 (year ended Dec 31, 2025), filed Feb 27, 2026
Sector classificationGICS via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

Solventum

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號SOLV(NYSE)
公司Solventum Corporation
GICS 板塊/行業醫療保健/Health Care Technology
標普500排名(按權重)第450名 · 0.02%(2026 年 11 月 4 日)
板塊內排名(按標普500權重)醫療保健第52名(2026 年 11 月 4 日)
總部明尼蘇達州梅普爾伍德
成立2024年,自 3M 分拆(分拆於2024年4月1日完成);此前為 3M 醫療保健業務
行政總裁Bryan Hanson(總裁兼行政總裁)
員工約20,000名員工(FY2025 10-K)
市值$14.43B(2026 年 11 月 4 日)
SEC 文件EDGAR — CIK 0001964738

業務概覽

Solventum 是一家於2024年4月1日自 3M 分拆出來的醫療保健公司。它報告三個板塊:MedSurg(負壓傷口治療、先進傷口敷料、先進皮膚護理、合成組織基質、靜脈置管管理、滅菌保證、體溫管理、外科用品、醫用膠帶及包紮、聽診器、電極及 OEM 技術);牙科解決方案(托槽、矯治器、修復水泥及黏合劑,涵蓋預防、修復、替換及錯頜畸形);以及健康資訊系統(電腦輔助醫生文件記錄、直接計費及編碼自動化、分類方法、語音識別及數據可視化,旨在消除收入週期浪費並支持基於價值的護理)。

FY2025 是公司作為獨立公司的首個完整曆年。淨銷售額為83.3億美元,增長0.9%,淨利潤為15.6億美元,即攤薄每股收益8.88美元,而2024年為4.79億美元,即2.76美元。這一比較並非清晰的趨勢指標:2025年包括於企業及未分配部門內的純化及過濾業務出售收益(於2025年9月1日完成),而2024年比較數字橫跨分拆。經調整攤薄每股收益(非 GAAP)為6.11美元,較6.70美元下跌8.8%。10-K 本身警告,歷史分拆前財務資料為分拆資料,不一定代表獨立公司的業績——因此本介紹不將分拆前數字作為獨立可比數字呈現。

純化及過濾業務根據2025年2月25日的協議,於2025年9月1日出售,於 FY2025 貢獻4.97億美元淨銷售額,僅涵蓋出售前的期間。保留的水務業務(此前屬於純化及過濾)連同 3M 供應協議下的銷售,一併於其他部門報告。2025年12月,Solventum 收購 Acera 作為全資子公司;於2025年12月31日,被收購業務的總資產及淨銷售額各佔綜合金額不足1%。

板塊 — FY2025 淨銷售額

板塊淨銷售額佔比同比
MedSurg48.2億美元57.9%+3.9%
牙科解決方案13.5億美元16.2%+4.2%
健康資訊系統13.6億美元16.3%+4.1%
純化及過濾5.0億美元6.0%−29.9%
其他3.0億美元3.6%−1.3%
板塊淨銷售額按 FY2025 10-K 附註18披露;五行合計等於83.25億美元。FY2024 比較數字:MedSurg 46.37億美元,牙科解決方案12.95億美元,健康資訊系統13.06億美元,純化及過濾7.09億美元,其他3.06億美元。純化及過濾於2025年9月1日出售,故 FY2025 銷售額僅涵蓋出售前的期間。自2025年第三季起,公司報告三個板塊(MedSurg、牙科解決方案、健康資訊系統),保留的水務業務列於其他部門。可報告板塊淨銷售額為75.26億美元(FY2024:72.38億美元)。

歷史沿革

年份里程碑
2024年之前該業務作為 3M 的醫療保健業務營運;其歷史財務資料為分拆資料,並非獨立業績。
2024年自 3M 的分拆於2024年4月1日完成;Solventum 以獨立上市公司的身份於紐約證券交易所上市。
2025年Solventum 於2025年2月25日同意出售純化及過濾業務,並於2025年9月1日完成出售;2025年12月收購 Acera 作為全資子公司。

競爭地位

  • MedSurg 是支柱(佔 FY2025 淨銷售額57.9%,板塊營運利潤8.10億美元),其傷口護理及外科品牌銷往全球醫院。
  • 牙科解決方案及健康資訊系統是較小的相鄰業務,2025年均增長約4%;健康資訊系統以13.60億美元淨銷售額錄得4.96億美元板塊營運利潤。
  • 與 Medtronic 及 BD 等多元醫療科技同業相比,Solventum 是專注於傷口護理、牙科及健康資訊科技的純粹業務——規模較小,分拆後仍在建立獨立成本基礎。

財務快照 — FY2025

淨銷售額83.3億美元
總營運利潤21.8億美元
所得稅前利潤17.1億美元
淨利潤15.6億美元
攤薄每股收益8.88美元
經調整攤薄每股收益(非 GAAP)6.11美元
淨利息支出3.47億美元
FY2025 截至2025年12月31日;10-K 於2026年2月27日提交。上年數字:淨銷售額82.5億美元,淨利潤4.79億美元,攤薄每股收益2.76美元,故淨銷售額增長0.9%,淨利潤增長224.8%(推算)。淨利潤比較並非清晰的趨勢指標:2025年包括於企業及未分配部門內的純化及過濾業務出售收益(於2025年9月1日完成),而2025年是自 3M 於2024年4月1日分拆後作為獨立公司的首個完整曆年;分拆前數字為分拆資料,並非獨立業績。經調整攤薄每股收益(非 GAAP)為6.11美元,較6.70美元下跌8.8%。總營運利潤21.81億美元來自附註18對賬(可報告板塊16.52億美元,純化及過濾0.96億美元,其他0.42億美元,攤銷−3.12億美元,企業及未分配+7.02億美元)。

主要風險

  • 分拆依賴風險:3M 過渡及供應協議以及獨立成本仍然重要;10-K 的風險摘要以此為首。
  • MedSurg 監管及產品責任風險:傷口護理及外科產品面臨 FDA 監管及責任索賠。
  • 牙科及健康資訊競爭與醫療系統客戶集中風險:兩個較小板塊均與更大型的多元供應商競爭。
  • 分拆帶來的債務風險(2025年淨利息支出3.47億美元),以及出售純化及過濾業務後規模及多元化程度下降。

對標普500的重要性

Solventum 是標普500中最新的獨立醫療保健公司:傷口護理量、牙科需求及健康資訊軟件採用情況,可反映醫院開支、牙科就診及向基於價值的護理轉變。按權重排名第450位(0.02%)——醫療保健第52名——它是一家分拆公司,在脫離 3M 後的首個完整年度,仍在證明其獨立成本結構。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 4 日抓取)· StockAnalysis(市值——2026 年 11 月 4 日抓取,單一來源)
財務FY2025 10-K(截至2025年12月31日的年度),2026年2月27日提交
板塊分類GICS,據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

Solventum

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · SOLV
Data as of Nov 4, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · Snap-on Incorporated (SNA) — XLI Industrials · S&P 500 Profile |Snap-on公司介紹Next · Assurant, Inc. (AIZ) — XLF Financials · S&P 500 Profile |Assurant公司介紹

Entered 2026-11-04 02:04 · updated 2026-11-15 00:02 · rev 5